1 2616 199 YOGA FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE. BACKGROUND: CORONARY HEART DISEASE (CHD) IS THE MAJOR CAUSE OF EARLY MORBIDITY AND MORTALITY IN MOST DEVELOPED COUNTRIES. SECONDARY PREVENTION AIMS TO PREVENT REPEAT CARDIAC EVENTS AND DEATH IN PEOPLE WITH ESTABLISHED CHD. LIFESTYLE MODIFICATIONS PLAY AN IMPORTANT ROLE IN SECONDARY PREVENTION. YOGA HAS BEEN REGARDED AS A TYPE OF PHYSICAL ACTIVITY AS WELL AS A STRESS MANAGEMENT STRATEGY. GROWING EVIDENCE SUGGESTS THE BENEFICIAL EFFECTS OF YOGA ON VARIOUS AILMENTS. OBJECTIVES: TO DETERMINE THE EFFECTIVENESS OF YOGA FOR THE SECONDARY PREVENTION OF MORTALITY AND MORBIDITY IN, AND ON THE HEALTH-RELATED QUALITY OF LIFE OF, INDIVIDUALS WITH CHD. SEARCH METHODS: THIS IS AN UPDATE OF A REVIEW PREVIOUSLY PUBLISHED IN 2012. FOR THIS UPDATED REVIEW, WE SEARCHED THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL) IN THE COCHRANE LIBRARY (ISSUE 1 OF 12, 2014), MEDLINE (1948 TO FEBRUARY WEEK 1 2014), EMBASE (1980 TO 2014 WEEK 6), WEB OF SCIENCE (THOMSON REUTERS, 1970 TO 12 FEBRUARY 2014), CHINA JOURNAL NET (1994 TO MAY 2014), WANFANG DATA (1990 TO MAY 2014), AND INDEX TO CHINESE PERIODICALS OF HONG KONG (HKINCHIP) (FROM 1980). ONGOING STUDIES WERE IDENTIFIED IN THE METAREGISTER OF CONTROLLED TRIALS (MAY 2014) AND THE WORLD HEALTH ORGANIZATION INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM (MAY 2014). WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: WE PLANNED TO INCLUDE RANDOMISED CONTROLLED TRIALS (RCTS) INVESTIGATING THE INFLUENCE OF YOGA PRACTICE ON CHD OUTCOMES IN MEN AND WOMEN (AGED 18 YEARS AND OVER) WITH A DIAGNOSIS OF ACUTE OR CHRONIC CHD. STUDIES WERE ELIGIBLE FOR INCLUSION IF THEY HAD A FOLLOW-UP DURATION OF SIX MONTHS OR MORE. WE CONSIDERED STUDIES THAT COMPARED ONE GROUP PRACTICING A TYPE OF YOGA WITH A CONTROL GROUP RECEIVING EITHER NO INTERVENTION OR INTERVENTIONS OTHER THAN YOGA. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SELECTED STUDIES ACCORDING TO PRESPECIFIED INCLUSION CRITERIA. WE RESOLVED DISAGREEMENTS EITHER BY CONSENSUS OR BY DISCUSSION WITH A THIRD AUTHOR. MAIN RESULTS: WE FOUND NO ELIGIBLE RCTS THAT MET THE INCLUSION CRITERIA OF THE REVIEW AND THUS WE WERE UNABLE TO PERFORM A META-ANALYSIS. AUTHORS' CONCLUSIONS: THE EFFECTIVENESS OF YOGA FOR SECONDARY PREVENTION IN CHD REMAINS UNCERTAIN. LARGE RCTS OF HIGH QUALITY ARE NEEDED. 2015 2 2543 89 YOGA FOR ASTHMA. BACKGROUND: ASTHMA IS A COMMON CHRONIC INFLAMMATORY DISORDER AFFECTING ABOUT 300 MILLION PEOPLE WORLDWIDE. AS A HOLISTIC THERAPY, YOGA HAS THE POTENTIAL TO RELIEVE BOTH THE PHYSICAL AND PSYCHOLOGICAL SUFFERING OF PEOPLE WITH ASTHMA, AND ITS POPULARITY HAS EXPANDED GLOBALLY. A NUMBER OF CLINICAL TRIALS HAVE BEEN CARRIED OUT TO EVALUATE THE EFFECTS OF YOGA PRACTICE, WITH INCONSISTENT RESULTS. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA IN PEOPLE WITH ASTHMA. SEARCH METHODS: WE SYSTEMATICALLY SEARCHED THE COCHRANE AIRWAYS GROUP REGISTER OF TRIALS, WHICH IS DERIVED FROM SYSTEMATIC SEARCHES OF BIBLIOGRAPHIC DATABASES INCLUDING THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, AND PSYCINFO, AND HANDSEARCHING OF RESPIRATORY JOURNALS AND MEETING ABSTRACTS. WE ALSO SEARCHED PEDRO. WE SEARCHED CLINICALTRIALS.GOV AND THE WHO ICTRP SEARCH PORTAL. WE SEARCHED ALL DATABASES FROM THEIR INCEPTION TO 22 JULY 2015, AND USED NO RESTRICTION ON LANGUAGE OF PUBLICATION. WE CHECKED THE REFERENCE LISTS OF ELIGIBLE STUDIES AND RELEVANT REVIEW ARTICLES FOR ADDITIONAL STUDIES. WE ATTEMPTED TO CONTACT INVESTIGATORS OF ELIGIBLE STUDIES AND EXPERTS IN THE FIELD TO LEARN OF OTHER PUBLISHED AND UNPUBLISHED STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMISED CONTROLLED TRIALS (RCTS) THAT COMPARED YOGA WITH USUAL CARE (OR NO INTERVENTION) OR SHAM INTERVENTION IN PEOPLE WITH ASTHMA AND REPORTED AT LEAST ONE OF THE FOLLOWING OUTCOMES: QUALITY OF LIFE, ASTHMA SYMPTOM SCORE, ASTHMA CONTROL, LUNG FUNCTION MEASURES, ASTHMA MEDICATION USAGE, AND ADVERSE EVENTS. DATA COLLECTION AND ANALYSIS: WE EXTRACTED BIBLIOGRAPHIC INFORMATION, CHARACTERISTICS OF PARTICIPANTS, CHARACTERISTICS OF INTERVENTIONS AND CONTROLS, CHARACTERISTICS OF METHODOLOGY, AND RESULTS FOR THE OUTCOMES OF OUR INTEREST FROM ELIGIBLE STUDIES. FOR CONTINUOUS OUTCOMES, WE USED MEAN DIFFERENCE (MD) WITH 95% CONFIDENCE INTERVAL (CI) TO DENOTE THE TREATMENT EFFECTS, IF THE OUTCOMES WERE MEASURED BY THE SAME SCALE ACROSS STUDIES. ALTERNATIVELY, IF THE OUTCOMES WERE MEASURED BY DIFFERENT SCALES ACROSS STUDIES, WE USED STANDARDISED MEAN DIFFERENCE (SMD) WITH 95% CI. FOR DICHOTOMOUS OUTCOMES, WE USED RISK RATIO (RR) WITH 95% CI TO MEASURE THE TREATMENT EFFECTS. WE PERFORMED META-ANALYSIS WITH REVIEW MANAGER 5.3. WE USED THE FIXED-EFFECT MODEL TO POOL THE DATA, UNLESS THERE WAS SUBSTANTIAL HETEROGENEITY AMONG STUDIES, IN WHICH CASE WE USED THE RANDOM-EFFECTS MODEL INSTEAD. FOR OUTCOMES INAPPROPRIATE OR IMPOSSIBLE TO POOL QUANTITATIVELY, WE CONDUCTED A DESCRIPTIVE ANALYSIS AND SUMMARISED THE FINDINGS NARRATIVELY. MAIN RESULTS: WE INCLUDED 15 RCTS WITH A TOTAL OF 1048 PARTICIPANTS. MOST OF THE TRIALS WERE CONDUCTED IN INDIA, FOLLOWED BY EUROPE AND THE UNITED STATES. THE MAJORITY OF PARTICIPANTS WERE ADULTS OF BOTH SEXES WITH MILD TO MODERATE ASTHMA FOR SIX MONTHS TO MORE THAN 23 YEARS. FIVE STUDIES INCLUDED YOGA BREATHING ALONE, WHILE THE OTHER STUDIES ASSESSED YOGA INTERVENTIONS THAT INCLUDED BREATHING, POSTURE, AND MEDITATION. INTERVENTIONS LASTED FROM TWO WEEKS TO 54 MONTHS, FOR NO MORE THAN SIX MONTHS IN THE MAJORITY OF STUDIES. THE RISK OF BIAS WAS LOW ACROSS ALL DOMAINS IN ONE STUDY AND UNCLEAR OR HIGH IN AT LEAST ONE DOMAIN FOR THE REMAINDER.THERE WAS SOME EVIDENCE THAT YOGA MAY IMPROVE QUALITY OF LIFE (MD IN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) SCORE PER ITEM 0.57 UNITS ON A 7-POINT SCALE, 95% CI 0.37 TO 0.77; 5 STUDIES; 375 PARTICIPANTS), IMPROVE SYMPTOMS (SMD 0.37, 95% CI 0.09 TO 0.65; 3 STUDIES; 243 PARTICIPANTS), AND REDUCE MEDICATION USAGE (RR 5.35, 95% CI 1.29 TO 22.11; 2 STUDIES) IN PEOPLE WITH ASTHMA. THE MD FOR AQLQ SCORE EXCEEDED THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) OF 0.5, BUT WHETHER THE MEAN CHANGES EXCEEDED THE MCID FOR ASTHMA SYMPTOMS IS UNCERTAIN DUE TO THE LACK OF AN ESTABLISHED MCID IN THE SEVERITY SCORES USED IN THE INCLUDED STUDIES. THE EFFECTS OF YOGA ON CHANGE FROM BASELINE FORCED EXPIRATORY VOLUME IN ONE SECOND (MD 0.04 LITRES, 95% CI -0.10 TO 0.19; 7 STUDIES; 340 PARTICIPANTS; I(2) = 68%) WERE NOT STATISTICALLY SIGNIFICANT. TWO STUDIES INDICATED IMPROVED ASTHMA CONTROL, BUT DUE TO VERY SIGNIFICANT HETEROGENEITY (I(2) = 98%) WE DID NOT POOL DATA. NO SERIOUS ADVERSE EVENTS ASSOCIATED WITH YOGA WERE REPORTED, BUT THE DATA ON THIS OUTCOME WAS LIMITED. AUTHORS' CONCLUSIONS: WE FOUND MODERATE-QUALITY EVIDENCE THAT YOGA PROBABLY LEADS TO SMALL IMPROVEMENTS IN QUALITY OF LIFE AND SYMPTOMS IN PEOPLE WITH ASTHMA. THERE IS MORE UNCERTAINTY ABOUT POTENTIAL ADVERSE EFFECTS OF YOGA AND ITS IMPACT ON LUNG FUNCTION AND MEDICATION USAGE. RCTS WITH A LARGE SAMPLE SIZE AND HIGH METHODOLOGICAL AND REPORTING QUALITY ARE NEEDED TO CONFIRM THE EFFECTS OF YOGA FOR ASTHMA. 2016 3 1061 60 EFFECTS OF YOGA ON HEALTH-RELATED QUALITY, PHYSICAL HEALTH AND PSYCHOLOGICAL HEALTH IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: YOGA RECEIVE MORE ATTENTION FROM BREAST CANCER PATIENTS, HOWEVER ITS FEASIBILITY AND EFFICACY DURING CHEMOTHERAPY REMAINS CONFLICTING. WE PERFORMED THIS SYSTEMATIC REVIEW TO ASSESS THE EFFECTS OF YOGA ON HEALTH-RELATED QUALITY, PHYSICAL HEALTH AND PSYCHOLOGICAL HEALTH IN BREAST CANCER PATIENTS UNDERGOING CHEMOTHERAPY. METHODS: A SYSTEMATIC SEARCH WAS CONDUCTED TO RETRIEVE RANDOMIZED CONTROLLED TRIALS (RCTS) WHICH INVESTIGATED THE COMPARATIVE EFFICACY OF YOGA VERSUS COMPARATORS SUCH AS USUAL CARE AMONG BREAST CANCER PATIENTS FOR HEALTH-RELATED QUALITY, PHYSICAL HEALTH AND PSYCHOLOGICAL HEALTH IN PUBMED, EMBASE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CNETRAL), NURSING AND ALLIED HEALTH LITERATURE (CINAHL), CHINESE BIOMEDICAL LITERATURE (CBM) DATABASE, CHINA SCIENCE AND TECHNOLOGY JOURNAL (CSTJ) DATABASE, CHINA NATIONAL KNOWLEDGE INFRASTRUCTURE (CNKI), AND WANGFANG DATABASE FROM INCEPTION TO DECEMBER 2018. THE LATEST SEARCH WAS UPDATED ON SEPTEMBER 2020. ALL ANALYSES WERE COMPLETED USING REVMAN VERSION 5.3. RESULTS: SEVEN TRIALS INVOLVING 693 BREAST CANCER PATIENTS MET INCLUSION CRITERIA. META-ANALYSIS INDICATED A SHORT-TERM IMPROVEMENT IN FATIGUE [STANDARD MEAN DIFFERENCE (SMD), -0.62; 95% CONFIDENCE INTERVAL (CI), -1.17 TO -0.07], SLEEP DISTURBANCE (SMD, -0.34; 95% CI, -0.55 TO -0.12), DEPRESSION (SMD, -0.50; 95% CI, -0.70 TO -0.31) ANXIETY (SMD, -0.50; 95% CI, -0.70 TO -0.31), AND HEALTH-RELATED QUALITY OF LIFE (QOL) (SMD, 0.72; 95% CI, -0.12 TO 1.56) IN THE YOGA GROUP; HOWEVER BENEFICIAL MEDIUM- AND LONG-TERM EFFECTS IN FATIGUE, SLEEP DISTURBANCE WERE NOT IDENTIFIED. MOREOVER, QUALITATIVE ANALYSES SUGGESTED THAT YOGA WAS NOT ASSOCIATED WITH DECREASED ADVERSE EVENTS (AES) COMPARED WITH CONTROL GROUPS. CONCLUSIONS: YOGA MAY BENEFIT TO REDUCE FATIGUE, DEPRESSION AND ANXIETY, IMPROVE SLEEP DISTURBANCE, AND IMPROVE QOL IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY IN THE SHORT-TERM; HOWEVER, MEDIUM- AND LONG-TERM EFFECTS SHOULD BE FURTHER ESTABLISHED OWING TO LIMITATIONS. 2021 4 2657 90 YOGA IN ADDITION TO STANDARD CARE FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. BACKGROUND: HAEMATOLOGICAL MALIGNANCIES ARE MALIGNANT NEOPLASMS OF THE MYELOID OR LYMPHATIC CELL LINES INCLUDING LEUKAEMIA, LYMPHOMA AND MYELOMA. IN ORDER TO MANAGE PHYSICAL AND PSYCHOLOGICAL ASPECTS OF THE DISEASE AND ITS TREATMENT, COMPLEMENTARY THERAPIES LIKE YOGA ARE COMING INCREASINGLY INTO FOCUS. HOWEVER, THE EFFECTIVENESS OF YOGA PRACTICE FOR PEOPLE SUFFERING FROM HAEMATOLOGICAL MALIGNANCIES REMAINS UNCLEAR. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA PRACTICE IN ADDITION TO STANDARD CANCER TREATMENT FOR PEOPLE WITH HAEMATOLOGICAL MALIGNANCIES. SEARCH METHODS: OUR SEARCH STRATEGY INCLUDED THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL), MEDLINE (1950 TO 4TH FEBRUARY 2014), DATABASES OF ONGOING TRIALS (CONTROLLED-TRIALS.COM; CLINICALTRIALS.GOV), CONFERENCE PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, THE AMERICAN SOCIETY OF HEMATOLOGY, THE EUROPEAN HAEMATOLOGY ASSOCIATION, THE EUROPEAN CONGRESS FOR INTEGRATIVE MEDICINE, AND GLOBAL ADVANCES IN HEALTH AND MEDICINE. WE HANDSEARCHED REFERENCES OF THESE STUDIES FROM IDENTIFIED TRIALS AND RELEVANT REVIEW ARTICLES. TWO REVIEW AUTHORS INDEPENDENTLY SCREENED THE SEARCH RESULTS. SELECTION CRITERIA: WE INCLUDED RANDOMISED CONTROLLED TRIALS (RCTS) OF YOGA IN ADDITION TO STANDARD CARE FOR HAEMATOLOGICAL MALIGNANCIES COMPARED WITH STANDARD CARE ONLY. WE DID NOT RESTRICT THIS TO ANY SPECIFIC STYLE OF YOGA. DATA COLLECTION AND ANALYSIS: TWO REVIEW AUTHORS INDEPENDENTLY EXTRACTED DATA FOR ELIGIBLE STUDIES AND ASSESSED THE RISK OF BIAS ACCORDING TO PREDEFINED CRITERIA. WE EVALUATED DISTRESS, FATIGUE, ANXIETY, DEPRESSION AND QUALITY OF SLEEP. FURTHER OUTCOMES WE PLANNED TO ASSESS WERE HEALTH-RELATED QUALITY OF LIFE (HRQOL), OVERALL SURVIVAL (OS) AND ADVERSE EVENTS (AE), BUT DATA ON THESE WERE NOT AVAILABLE. MAIN RESULTS: OUR SEARCH STRATEGIES LED TO 149 POTENTIALLY RELEVANT REFERENCES, BUT ONLY A SINGLE SMALL STUDY MET OUR INCLUSION CRITERIA. THE INCLUDED STUDY WAS PUBLISHED AS A FULL TEXT ARTICLE AND INVESTIGATED THE FEASIBILITY AND EFFECT OF TIBETAN YOGA ADDITIONAL TO STANDARD CARE (N = 20; 1 PERSON DROPPED OUT BEFORE ATTENDING ANY CLASSES AND NO DATA WERE COLLECTED) COMPARED TO STANDARD CARE ONLY (N = 19). THE STUDY INCLUDED PEOPLE WITH ALL STAGES OF HODGKIN AND NON-HODGKIN'S LYMPHOMA, WITH AND WITHOUT CURRENT CANCER TREATMENT. THE MEAN AGE WAS 51 YEARS.WE JUDGED THE OVERALL RISK OF BIAS AS HIGH AS WE FOUND A HIGH RISK FOR PERFORMANCE, DETECTION AND ATTRITION BIAS. ADDITIONALLY, POTENTIAL OUTCOME REPORTING BIAS COULD NOT BE COMPLETELY RULED OUT. FOLLOWING THE RECOMMENDATIONS OF GRADE, WE JUDGED THE OVERALL QUALITY OF THE BODY OF EVIDENCE FOR ALL PREDEFINED OUTCOMES AS 'VERY LOW', DUE TO THE METHODICAL LIMITATIONS AND THE VERY SMALL SAMPLE SIZE.THE INFLUENCE OF YOGA ON HRQOL AND OS WAS NOT REPORTED. THERE IS NO EVIDENCE THAT YOGA IN ADDITION TO STANDARD CARE COMPARED WITH STANDARD CARE ONLY CAN IMPROVE DISTRESS IN PEOPLE WITH HAEMATOLOGICAL MALIGNANCIES (MEAN DIFFERENCE (MD) -0.30, 95% CONFIDENCE INTERVAL (CI) -5.55 TO 4.95; P = 0.91). SIMILARLY, THERE IS NO EVIDENCE OF A DIFFERENCE BETWEEN EITHER GROUP FOR FATIGUE (MD 0.00, 95% CI -0.94 TO 0.94; P = 1.00), ANXIETY (MD 0.30, 95% CI -5.01 TO 5.61; P = 0.91) OR DEPRESSION (MD -0.70, 95% CI -3.21 TO 1.81; P = 0.58).THERE IS VERY LOW QUALITY EVIDENCE THAT YOGA IMPROVES THE OVERALL QUALITY OF SLEEP (MD -2.30, 95% CI -3.78 TO -0.82; P = 0.002). THE YOGA GROUPS' TOTAL SCORE FOR THE PITTSBURGH SLEEP QUALITY INDEX (PSQI) WAS 5.8 (+/- 2.3 SD) AND BETTER THAN THE TOTAL SCORE (8.1 (+/- 2.4 SD)) OF THE CONTROL GROUP. A PSQI TOTAL SCORE OF 0 TO 5 INDICATES GOOD SLEEP WHEREAS PSQI TOTAL SCORE 6 TO 21 POINTS TOWARDS SIGNIFICANT SLEEP DISTURBANCES. THE OCCURRENCE OF AES WAS NOT REPORTED. AUTHORS' CONCLUSIONS: THE CURRENTLY AVAILABLE DATA PROVIDE LITTLE INFORMATION ABOUT THE EFFECTIVENESS OF YOGA INTERVENTIONS FOR PEOPLE SUFFERING FROM HAEMATOLOGICAL MALIGNANCIES. THE FINDING THAT YOGA MAY BE BENEFICIAL FOR THE PATIENTS' QUALITY OF SLEEP IS BASED ON A VERY SMALL BODY OF EVIDENCE. THEREFORE, THE ROLE OF YOGA AS AN ADDITIONAL THERAPY FOR HAEMATOLOGICAL MALIGNANCIES REMAINS UNCLEAR. FURTHER HIGH-QUALITY RANDOMISED CONTROLLED TRIALS WITH LARGER NUMBERS OF PARTICIPANTS ARE NEEDED TO MAKE A DEFINITIVE STATEMENT. 2014 5 2629 92 YOGA FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE. BACKGROUND: A SEDENTARY LIFESTYLE AND STRESS ARE MAJOR RISK FACTORS FOR CARDIOVASCULAR DISEASE (CVD). SINCE YOGA INVOLVES EXERCISE AND IS THOUGHT TO HELP IN STRESS REDUCTION IT MAY BE AN EFFECTIVE STRATEGY IN THE PRIMARY PREVENTION OF CVD. OBJECTIVES: TO DETERMINE THE EFFECT OF ANY TYPE OF YOGA ON THE PRIMARY PREVENTION OF CVD. SEARCH METHODS: WE SEARCHED THE FOLLOWING ELECTRONIC DATABASES: THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL) (2013, ISSUE 11) IN THE COCHRANE LIBRARY; MEDLINE (OVID) (1946 TO NOVEMBER WEEK 3 2013); EMBASE CLASSIC + EMBASE (OVID) (1947 TO 2013 WEEK 48); WEB OF SCIENCE (THOMSON REUTERS) (1970 TO 4 DECEMBER 2013); DATABASE OF ABSTRACTS OF REVIEWS OF EFFECTS (DARE), HEALTH TECHNOLOGY ASSESSMENT DATABASE AND HEALTH ECONOMICS EVALUATIONS DATABASE (ISSUE 4 OF 4, 2013) IN THE COCHRANE LIBRARY. WE ALSO SEARCHED A NUMBER OF ASIAN DATABASES AND THE ALLIED AND COMPLEMENTARY MEDICINE DATABASE (AMED) (INCEPTION TO DECEMBER 2012). WE SEARCHED TRIAL REGISTERS AND REFERENCE LISTS OF REVIEWS AND ARTICLES, AND APPROACHED EXPERTS IN THE FIELD. WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS LASTING AT LEAST THREE MONTHS INVOLVING HEALTHY ADULTS OR THOSE AT HIGH RISK OF CVD. TRIALS EXAMINED ANY TYPE OF YOGA AND THE COMPARISON GROUP WAS NO INTERVENTION OR MINIMAL INTERVENTION. OUTCOMES OF INTEREST WERE CLINICAL CVD EVENTS AND MAJOR CVD RISK FACTORS. WE DID NOT INCLUDE ANY TRIALS THAT INVOLVED MULTIFACTORIAL LIFESTYLE INTERVENTIONS OR WEIGHT LOSS. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SELECTED TRIALS FOR INCLUSION, EXTRACTED DATA AND ASSESSED THE RISK OF BIAS. MAIN RESULTS: WE IDENTIFIED 11 TRIALS (800 PARTICIPANTS) AND TWO ONGOING STUDIES. STYLE AND DURATION OF YOGA DIFFERED BETWEEN TRIALS. HALF OF THE PARTICIPANTS RECRUITED TO THE STUDIES WERE AT HIGH RISK OF CVD. MOST OF STUDIES WERE AT RISK OF PERFORMANCE BIAS, WITH INADEQUATE DETAILS REPORTED IN MANY OF THEM TO JUDGE THE RISK OF SELECTION BIAS.NO STUDY REPORTED CARDIOVASCULAR MORTALITY, ALL-CAUSE MORTALITY OR NON-FATAL EVENTS, AND MOST STUDIES WERE SMALL AND SHORT-TERM. THERE WAS SUBSTANTIAL HETEROGENEITY BETWEEN STUDIES MAKING IT IMPOSSIBLE TO COMBINE STUDIES STATISTICALLY FOR SYSTOLIC BLOOD PRESSURE AND TOTAL CHOLESTEROL. YOGA WAS FOUND TO PRODUCE REDUCTIONS IN DIASTOLIC BLOOD PRESSURE (MEAN DIFFERENCE (MD) -2.90 MMHG, 95% CONFIDENCE INTERVAL (CI) -4.52 TO -1.28), WHICH WAS STABLE ON SENSITIVITY ANALYSIS, TRIGLYCERIDES (MD -0.27 MMOL/L, 95% CI -0.44 TO -0.11) AND HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL (MD 0.08 MMOL/L, 95% CI 0.02 TO 0.14). HOWEVER, THE CONTRIBUTING STUDIES WERE SMALL, SHORT-TERM AND AT UNCLEAR OR HIGH RISK OF BIAS. THERE WAS NO CLEAR EVIDENCE OF A DIFFERENCE BETWEEN GROUPS FOR LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL (MD -0.09 MMOL/L, 95% CI -0.48 TO 0.30), ALTHOUGH THERE WAS MODERATE STATISTICAL HETEROGENEITY. ADVERSE EVENTS, OCCURRENCE OF TYPE 2 DIABETES AND COSTS WERE NOT REPORTED IN ANY OF THE INCLUDED STUDIES. QUALITY OF LIFE WAS MEASURED IN THREE TRIALS BUT THE RESULTS WERE INCONCLUSIVE. AUTHORS' CONCLUSIONS: THE LIMITED EVIDENCE COMES FROM SMALL, SHORT-TERM, LOW-QUALITY STUDIES. THERE IS SOME EVIDENCE THAT YOGA HAS FAVOURABLE EFFECTS ON DIASTOLIC BLOOD PRESSURE, HDL CHOLESTEROL AND TRIGLYCERIDES, AND UNCERTAIN EFFECTS ON LDL CHOLESTEROL. THESE RESULTS SHOULD BE CONSIDERED AS EXPLORATORY AND INTERPRETED WITH CAUTION. 2014 6 2597 44 YOGA FOR MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. WHILE YOGA SEEMS TO BE EFFECTIVE IN A NUMBER OF NEUROPSYCHIATRIC DISORDERS, THE EVIDENCE OF EFFICACY IN MULTIPLE SCLEROSIS REMAINS UNCLEAR. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE AVAILABLE DATA ON EFFICACY AND SAFETY OF YOGA IN PATIENTS WITH MULTIPLE SCLEROSIS. MEDLINE/PUBMED, SCOPUS, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, PSYCINFO, CAM-QUEST, CAMBASE, AND INDMED WERE SEARCHED THROUGH MARCH 2014. RANDOMIZED CONTROLLED TRIALS (RCTS) OF YOGA FOR PATIENTS WITH MULTIPLE SCLEROSIS WERE INCLUDED IF THEY ASSESSED HEALTH-RELATED QUALITY OF LIFE, FATIGUE, AND/OR MOBILITY. MOOD, COGNITIVE FUNCTION, AND SAFETY WERE DEFINED AS SECONDARY OUTCOME MEASURES. RISK OF BIAS WAS ASSESSED USING THE COCHRANE TOOL. SEVEN RCTS WITH A TOTAL OF 670 PATIENTS WERE INCLUDED. EVIDENCE FOR SHORT-TERM EFFECTS OF YOGA COMPARED TO USUAL CARE WERE FOUND FOR FATIGUE (STANDARDIZED MEAN DIFFERENCE [SMD] = -0.52; 95% CONFIDENCE INTERVALS (CI) = -1.02 TO -0.02; P = 0.04; HETEROGENEITY: I2 = 60%; CHI2 = 7.43; P = 0.06) AND MOOD (SMD = -0.55; 95%CI = -0.96 TO -0.13; P = 0.01; HETEROGENEITY: I2 = 0%; CHI2 = 1.25; P = 0.53), BUT NOT FOR HEALTH-RELATED QUALITY OF LIFE, MUSCLE FUNCTION, OR COGNITIVE FUNCTION. THE EFFECTS ON FATIGUE AND MOOD WERE NOT ROBUST AGAINST BIAS. NO SHORT-TERM OR LONGER TERM EFFECTS OF YOGA COMPARED TO EXERCISE WERE FOUND. YOGA WAS NOT ASSOCIATED WITH SERIOUS ADVERSE EVENTS. IN CONCLUSION, SINCE NO METHODOLOGICAL SOUND EVIDENCE WAS FOUND, NO RECOMMENDATION CAN BE MADE REGARDING YOGA AS A ROUTINE INTERVENTION FOR PATIENTS WITH MULTIPLE SCLEROSIS. YOGA MIGHT BE CONSIDERED A TREATMENT OPTION FOR PATIENTS WHO ARE NOT ADHERENT TO RECOMMENDED EXERCISE REGIMENS. 2014 7 834 54 EFFECT OF YOGA ON OXIDATIVE STRESS IN TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: DIABETES MELLITUS HAS A SIGNIFICANT IMPACT ON PUBLIC HEALTH. OXIDATIVE STRESS PLAYS A MAJOR ROLE IN THE PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS (T2DM), LEADING TO VARIOUS COMPLICATIONS OF T2DM. YOGA IS BEING WIDELY USED IN THE MANAGEMENT OF T2DM. THE PRIMARY OBJECTIVE OF THIS SYSTEMATIC REVIEW AND META-ANALYSIS IS TO UNDERSTAND THE EFFECTS OF YOGA ON OXIDATIVE STRESS PARAMETERS AMONG ADULT PATIENTS DIAGNOSED WITH T2DM. MATERIALS AND METHODS: ELECTRONIC DATABASES SUCH AS PUBMED, SCOPUS, COCHRANE LIBRARY AND SCIENCE DIRECT FROM START OF THE STUDY TILL MARCH 2020 WERE SEARCHED TO OBTAIN ELIGIBLE STUDIES. STUDY DESIGNS OF ALL NATURE WERE INCLUDED (EXCEPT CASE STUDIES AND REVIEWS). THE PRIMARY OUTCOME WAS MALONDIALDEHYDE (MDA) AND SECONDARY OUTCOMES INCLUDED FASTING PLASMA GLUCOSE, HBA1C AND SUPEROXIDE DISMUTASE (SOD) LEVELS. RESULTS: A TOTAL OF FOUR TRIALS WITH A TOTAL OF 440 PATIENTS MET THE INCLUSION CRITERIA. THE RESULTS OF META-ANALYSIS INDICATED THAT YOGA SIGNIFICANTLY REDUCED MDA (SMD: -1.4; 95% CI -2.66 TO -0.13; P = 0.03; I2 = 97%), FASTING PLASMA GLUCOSE LEVELS (SMD: -1.87: 95% CI -3.83 TO -0.09; P = 0.06; I2= 99%), AND HBA1C (SMD: -1.92; 95% CI - 3.03 TO -0.81; P = 0.0007; I2 = 92%) IN PATIENTS WITH T2DM. NO SUCH EFFECT WAS FOUND FOR SOD (SMD: -1.01; 95% CI -4.41 TO 2.38; P = 0.56; I2= 99%). CONCLUSION: THE AVAILABLE EVIDENCE SUGGESTS THAT YOGA REDUCES MDA, FASTING PLASMA GLUCOSE AND HBA1C, AND THUS WOULD BE BENEFICIAL IN THE MANAGEMENT OF T2DM AS A COMPLEMENTARY THERAPY. HOWEVER, CONSIDERING THE LIMITED NUMBER OF STUDIES AND ITS HETEROGENEITY, FURTHER ROBUST STUDIES ARE NECESSARY TO STRENGTHEN OUR FINDINGS AND INVESTIGATE THE LONG-TERM BENEFITS OF YOGA. 2022 8 1038 57 EFFECTS OF YOGA IN PATIENTS WITH CHRONIC HEART FAILURE: A META-ANALYSIS. THE USE OF YOGA AS AN EFFECTIVE CARDIAC REHABILITATION IN PATIENTS WITH CHRONIC HEART FAILURE (CHF) REMAINS CONTROVERSIAL. WE PERFORMED A META-ANALYSIS TO EXAMINE THE EFFECTS OF YOGA ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH CHF. METHODS: WE SEARCHED MEDLINE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, EXCERPTA MEDICA DATABASE, LILACS, PHYSIOTHERAPY EVIDENCE DATABASE, THE SCIENTIFIC ELECTRONIC LIBRARY ONLINE, AND CUMULATIVE INDEX TO NURSING AND ALLIED HEALTH (FROM THE EARLIEST DATE AVAILABLE TO DECEMBER 2013) FOR RANDOMIZED CONTROLLED TRIALS (RCTS) EXAMINING THE EFFECTS OF YOGA VERSUS EXERCISE AND/OR OF YOGA VERSUS CONTROL ON EXERCISE CAPACITY (PEAKVO2) AND QUALITY-OF-LIFE (HRQOL) IN CHF. TWO REVIEWERS SELECTED STUDIES INDEPENDENTLY. WEIGHTED MEAN DIFFERENCES (WMDS) AND 95% CONFIDENCE INTERVALS (CIS) WERE CALCULATED, AND HETEROGENEITY WAS ASSESSED USING THE I2 TEST. TWO STUDIES MET THE SELECTION CRITERIA (TOTAL: 30 YOGA AND 29 CONTROL PATIENTS). THE RESULTS SUGGESTED THAT YOGA COMPARED WITH CONTROL HAD A POSITIVE IMPACT ON PEAK VO2 AND HRQOL. PEAK VO2, WMD (3.87 95% CI: 1.95 TO 5.80), AND GLOBAL HRQOL STANDARDIZED MEAN DIFFERENCES (-12.46 95% CI: -22.49 TO -2.43) IMPROVED IN THE YOGA GROUP COMPARED TO THE CONTROL GROUP. YOGA ENHANCES PEAK VO2 AND HRQOL IN PATIENTS WITH CHF AND COULD BE CONSIDERED FOR INCLUSION IN CARDIAC REHABILITATION PROGRAMS. LARGER RCTS ARE REQUIRED TO FURTHER INVESTIGATE THE EFFECTS OF YOGA IN PATIENTS WITH CHF. 2014 9 2594 46 YOGA FOR METABOLIC SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND METABOLIC SYNDROME IS THE MOST IMPORTANT RISK FACTOR FOR DEVELOPING CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND PERFORM A META-ANALYSIS OF THE EFFECTS OF YOGA ON THE PARAMETERS OF METABOLIC SYNDROME. METHODS MEDLINE/PUBMED, SCOPUS, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS AND INDMED WERE SEARCHED AND SCREENED FROM THEIR INCEPTION THROUGH TO 8 MARCH 2016 FOR RANDOMISED CONTROLLED TRIALS ON YOGA FOR PATIENTS WITH METABOLIC SYNDROME. RISK OF BIAS WAS ASSESSED USING THE COCHRANE RISK OF BIAS TOOL. RESULTS SEVEN TRIALS WITH A TOTAL OF 794 PARTICIPANTS WERE INCLUDED. NO EFFECTS OF YOGA ON RESOLUTION OF METABOLIC SYNDROME, DIASTOLIC BLOOD PRESSURE, TRIGLYCERIDES, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND FASTING PLASMA GLUCOSE WERE FOUND, BUT YOGA WAS SUPERIOR TO USUAL CARE FOR WAIST CIRCUMFERENCE (STANDARDISED MEAN DIFFERENCE (SMD) = -0.35; 95% CONFIDENCE INTERVAL (CI) = -0.57 TO -0.13; P < 0.01) AND SYSTOLIC BLOOD PRESSURE (SMD = -0.29; 95% CI = -0.51 TO -0.07; P = 0.01). HOWEVER, THESE EFFECTS WERE NOT ROBUST AGAINST SELECTION BIAS. NO INTERVENTION-RELATED ADVERSE EVENTS WERE REPORTED. CONCLUSION BASED ON THE RESULTS OF THIS META-ANALYSIS, NO RECOMMENDATION CAN BE MADE FOR OR AGAINST YOGA IN ORDER TO INFLUENCE THE PARAMETERS OF METABOLIC SYNDROME. DESPITE METHODOLOGICAL DRAWBACKS, AND UNTIL FURTHER RESEARCH IS UNDERTAKEN, YOGA CAN BE PRELIMINARILY CONSIDERED AS A SAFE AND EFFECTIVE INTERVENTION FOR REDUCING WAIST CIRCUMFERENCE AND SYSTOLIC BLOOD PRESSURE IN INDIVIDUALS WITH METABOLIC SYNDROME WHO ARE NOT ADHERING TO CONVENTIONAL FORMS OF EXERCISE. 2016 10 2544 47 YOGA FOR ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: ALTHOUGH YOGA IS FREQUENTLY USED BY PATIENTS WITH ASTHMA, ITS EFFICACY IN ALLEVIATING ASTHMA REMAINS UNCLEAR. OBJECTIVE: TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE AVAILABLE DATA ON EFFICACY AND SAFETY OF YOGA IN ALLEVIATING ASTHMA. METHODS: MEDLINE/PUBMED, SCOPUS, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, PSYCINFO, CAM-QUEST, CAMBASE, AND INDMED WERE SEARCHED THROUGH JANUARY 2014. RANDOMIZED CONTROLLED TRIALS OF YOGA FOR PATIENTS WITH ASTHMA WERE INCLUDED IF THEY ASSESSED ASTHMA CONTROL, SYMPTOMS, QUALITY OF LIFE, AND/OR PULMONARY FUNCTION. FOR EACH OUTCOME, STANDARDIZED MEAN DIFFERENCES (SMDS) OR RISK RATIOS (RRS) AND 95% CONFIDENCE INTERVALS (CIS) WERE CALCULATED. RISK OF BIAS WAS ASSESSED USING THE COCHRANE TOOL. RESULTS: FOURTEEN RANDOMIZED CONTROLLED TRIALS WITH 824 PATIENTS WERE INCLUDED. EVIDENCE FOR EFFECTS OF YOGA COMPARED WITH USUAL CARE WAS FOUND FOR ASTHMA CONTROL (RR, 10.64; 95% CI, 1.98 TO 57.19; P = .006), ASTHMA SYMPTOMS (SMD, -0.37; 95% CI, -0.55 TO -0.19; P < .001), QUALITY OF LIFE (SMD, 0.86; 95% CI, 0.39 TO 1.33; P < .001), PEAK EXPIRATORY FLOW RATE (SMD, 0.49; 95% CI, 0.32 TO 0.67; P < .001), AND RATIO OF FORCED EXPIRATORY VOLUME IN 1 SECOND TO FORCED VITAL CAPACITY (SMD, 0.50; 95% CI, 0.24 TO 0.75; P < .001); EVIDENCE FOR EFFECTS OF YOGA COMPARED WITH PSYCHOLOGICAL INTERVENTIONS WAS FOUND FOR QUALITY OF LIFE (SMD, 0.61; 95% CI, 0.22 TO 0.99; P = .002) AND PEAK EXPIRATORY FLOW RATE (SMD, 2.87; 95% CI, 0.14 TO 5.60; P = .04). NO EVIDENCE FOR EFFECTS OF YOGA COMPARED WITH SHAM YOGA OR BREATHING EXERCISES WAS REVEALED. NO EFFECT WAS ROBUST AGAINST ALL POTENTIAL SOURCES OF BIAS. YOGA WAS NOT ASSOCIATED WITH SERIOUS ADVERSE EVENTS. CONCLUSION: YOGA CANNOT BE CONSIDERED A ROUTINE INTERVENTION FOR ASTHMATIC PATIENTS AT THIS POINT. IT CAN BE CONSIDERED AN ANCILLARY INTERVENTION OR AN ALTERNATIVE TO BREATHING EXERCISES FOR ASTHMA PATIENTS INTERESTED IN COMPLEMENTARY INTERVENTIONS. 2014 11 2587 91 YOGA FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS IN WOMEN DIAGNOSED WITH BREAST CANCER. BACKGROUND: BREAST CANCER IS THE CANCER MOST FREQUENTLY DIAGNOSED IN WOMEN WORLDWIDE. EVEN THOUGH SURVIVAL RATES ARE CONTINUALLY INCREASING, BREAST CANCER IS OFTEN ASSOCIATED WITH LONG-TERM PSYCHOLOGICAL DISTRESS, CHRONIC PAIN, FATIGUE AND IMPAIRED QUALITY OF LIFE. YOGA COMPRISES ADVICE FOR AN ETHICAL LIFESTYLE, SPIRITUAL PRACTICE, PHYSICAL ACTIVITY, BREATHING EXERCISES AND MEDITATION. IT IS A COMPLEMENTARY THERAPY THAT IS COMMONLY RECOMMENDED FOR BREAST CANCER-RELATED IMPAIRMENTS AND HAS BEEN SHOWN TO IMPROVE PHYSICAL AND MENTAL HEALTH IN PEOPLE WITH DIFFERENT CANCER TYPES. OBJECTIVES: TO ASSESS EFFECTS OF YOGA ON HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS AMONG WOMEN WITH A DIAGNOSIS OF BREAST CANCER WHO ARE RECEIVING ACTIVE TREATMENT OR HAVE COMPLETED TREATMENT. SEARCH METHODS: WE SEARCHED THE COCHRANE BREAST CANCER SPECIALISED REGISTER, MEDLINE (VIA PUBMED), EMBASE, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL; 2016, ISSUE 1), INDEXING OF INDIAN MEDICAL JOURNALS (INDMED), THE WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM (ICTRP) SEARCH PORTAL AND CLINICALTRIALS.GOV ON 29 JANUARY 2016. WE ALSO SEARCHED REFERENCE LISTS OF IDENTIFIED RELEVANT TRIALS OR REVIEWS, AS WELL AS CONFERENCE PROCEEDINGS OF THE INTERNATIONAL CONGRESS ON COMPLEMENTARY MEDICINE RESEARCH (ICCMR), THE EUROPEAN CONGRESS FOR INTEGRATIVE MEDICINE (ECIM) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS WERE ELIGIBLE WHEN THEY (1) COMPARED YOGA INTERVENTIONS VERSUS NO THERAPY OR VERSUS ANY OTHER ACTIVE THERAPY IN WOMEN WITH A DIAGNOSIS OF NON-METASTATIC OR METASTATIC BREAST CANCER, AND (2) ASSESSED AT LEAST ONE OF THE PRIMARY OUTCOMES ON PATIENT-REPORTED INSTRUMENTS, INCLUDING HEALTH-RELATED QUALITY OF LIFE, DEPRESSION, ANXIETY, FATIGUE OR SLEEP DISTURBANCES. DATA COLLECTION AND ANALYSIS: TWO REVIEW AUTHORS INDEPENDENTLY COLLECTED DATA ON METHODS AND RESULTS. WE EXPRESSED OUTCOMES AS STANDARDISED MEAN DIFFERENCES (SMDS) WITH 95% CONFIDENCE INTERVALS (CIS) AND CONDUCTED RANDOM-EFFECTS MODEL META-ANALYSES. WE ASSESSED POTENTIAL RISK OF PUBLICATION BIAS THROUGH VISUAL ANALYSIS OF FUNNEL PLOT SYMMETRY AND HETEROGENEITY BETWEEN STUDIES BY USING THE CHI(2) TEST AND THE I(2) STATISTIC. WE CONDUCTED SUBGROUP ANALYSES FOR CURRENT TREATMENT STATUS, TIME SINCE DIAGNOSIS, STAGE OF CANCER AND TYPE OF YOGA INTERVENTION. MAIN RESULTS: WE INCLUDED 24 STUDIES WITH A TOTAL OF 2166 PARTICIPANTS, 23 OF WHICH PROVIDED DATA FOR META-ANALYSIS. THIRTEEN STUDIES HAD LOW RISK OF SELECTION BIAS, FIVE STUDIES REPORTED ADEQUATE BLINDING OF OUTCOME ASSESSMENT AND 15 STUDIES HAD LOW RISK OF ATTRITION BIAS.SEVENTEEN STUDIES THAT COMPARED YOGA VERSUS NO THERAPY PROVIDED MODERATE-QUALITY EVIDENCE SHOWING THAT YOGA IMPROVED HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.22, 95% CI 0.04 TO 0.40; 10 STUDIES, 675 PARTICIPANTS), REDUCED FATIGUE (POOLED SMD -0.48, 95% CI -0.75 TO -0.20; 11 STUDIES, 883 PARTICIPANTS) AND REDUCED SLEEP DISTURBANCES IN THE SHORT TERM (POOLED SMD -0.25, 95% CI -0.40 TO -0.09; SIX STUDIES, 657 PARTICIPANTS). THE FUNNEL PLOT FOR HEALTH-RELATED QUALITY OF LIFE WAS ASYMMETRICAL, FAVOURING NO THERAPY, AND THE FUNNEL PLOT FOR FATIGUE WAS ROUGHLY SYMMETRICAL. THIS HINTS AT OVERALL LOW RISK OF PUBLICATION BIAS. YOGA DID NOT APPEAR TO REDUCE DEPRESSION (POOLED SMD -0.13, 95% CI -0.31 TO 0.05; SEVEN STUDIES, 496 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR ANXIETY (POOLED SMD -0.53, 95% CI -1.10 TO 0.04; SIX STUDIES, 346 PARTICIPANTS; VERY LOW-QUALITY EVIDENCE) IN THE SHORT TERM AND HAD NO MEDIUM-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.10, 95% CI -0.23 TO 0.42; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR FATIGUE (POOLED SMD -0.04, 95% CI -0.36 TO 0.29; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE). INVESTIGATORS REPORTED NO SERIOUS ADVERSE EVENTS.FOUR STUDIES THAT COMPARED YOGA VERSUS PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS PROVIDED MODERATE-QUALITY EVIDENCE INDICATING THAT YOGA CAN REDUCE DEPRESSION (POOLED SMD -2.29, 95% CI -3.97 TO -0.61; FOUR STUDIES, 226 PARTICIPANTS), ANXIETY (POOLED SMD -2.21, 95% CI -3.90 TO -0.52; THREE STUDIES, 195 PARTICIPANTS) AND FATIGUE (POOLED SMD -0.90, 95% CI -1.31 TO -0.50; TWO STUDIES, 106 PARTICIPANTS) IN THE SHORT TERM. VERY LOW-QUALITY EVIDENCE SHOWED NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.81, 95% CI -0.50 TO 2.12; TWO STUDIES, 153 PARTICIPANTS) OR SLEEP DISTURBANCES (POOLED SMD -0.21, 95% CI -0.76 TO 0.34; TWO STUDIES, 119 PARTICIPANTS). NO TRIAL ADEQUATELY REPORTED SAFETY-RELATED DATA.THREE STUDIES THAT COMPARED YOGA VERSUS EXERCISE PRESENTED VERY LOW-QUALITY EVIDENCE SHOWING NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD -0.04, 95% CI -0.30 TO 0.23; THREE STUDIES, 233 PARTICIPANTS) OR FATIGUE (POOLED SMD -0.21, 95% CI -0.66 TO 0.25; THREE STUDIES, 233 PARTICIPANTS); NO TRIAL PROVIDED SAFETY-RELATED DATA. AUTHORS' CONCLUSIONS: MODERATE-QUALITY EVIDENCE SUPPORTS THE RECOMMENDATION OF YOGA AS A SUPPORTIVE INTERVENTION FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE AND REDUCING FATIGUE AND SLEEP DISTURBANCES WHEN COMPARED WITH NO THERAPY, AS WELL AS FOR REDUCING DEPRESSION, ANXIETY AND FATIGUE, WHEN COMPARED WITH PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS. VERY LOW-QUALITY EVIDENCE SUGGESTS THAT YOGA MIGHT BE AS EFFECTIVE AS OTHER EXERCISE INTERVENTIONS AND MIGHT BE USED AS AN ALTERNATIVE TO OTHER EXERCISE PROGRAMMES. 2017 12 1064 45 EFFECTS OF YOGA ON IMMUNE FUNCTION: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS. OBJECTIVE: THIS SYSTEMATIC REVIEW ATTEMPTS TO CONFIRM THE ADDED EVIDENCE TO ASSESS THE EFFECT OF YOGA ON IMMUNE FUNCTION. METHODS: THE COCHRANE LIBRARY, EMBASE, PSYCINFO, PUBMED, AND WEB OF SCIENCE ELECTRONIC DATABASES WERE SEARCHED ACCORDING TO THE PRISRMA METHOD TO IDENTIFY RANDOMIZED CONTROLLED TRIALS (RCTS) ON THE IMMUNOLOGICAL EFFECTS OF YOGA PUBLISHED IN THE ENGLISH LANGUAGE FROM JANUARY 1, 2017, TO DECEMBER 31, 2020. THIS REVIEW COULD ONLY BE DESCRIPTIVELY SUMMARIZED BECAUSE OF HETEROGENEITY OF THE INCLUDED RCTS. RESULTS: ELEVEN POTENTIAL TRIALS WERE IDENTIFIED AND INCLUDED IN THIS REVIEW. QUALITY APPRAISAL OF INCLUDED TRIALS RANGED FROM 3 FOR UNCLEAR RISK OF BIAS AND 8 FOR HIGH RISK OF BIAS. THERE IS EVIDENCE FROM 11 RCTS THAT YOGA MAY HAVE FAVORABLE EFFECTS FOR REDUCING THE LEVELS OF ANTI-INFLAMMATORY MARKERS. CONCLUSIONS: YOGA MAY BE USED AS A COMPLEMENTARY INTERVENTION FOR CLINICAL POPULATIONS OR HEALTHY INDIVIDUALS. 2021 13 1202 42 EXERCISE, YOGA, AND TAI CHI FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN OUTPATIENT SETTINGS: A SYSTEMATIC REVIEW AND META-ANALYSIS. OBJECTIVE: EXERCISE, YOGA, AND TAI CHI ARE COMMONLY USED COMPLEMENTARY APPROACHES FOR HEALTH AND WELLNESS. THIS REVIEW AIMS TO SYNTHESIZE THE EVIDENCE FOR EXERCISE, YOGA, AND TAI CHI IN THE OUTPATIENT TREATMENT OF MAJOR DEPRESSIVE DISORDER. STUDY SELECTION: A SYSTEMATIC SEARCH OF THE OVID MEDLINE, EMBASE, PSYCINFO, AND COCHRANE DATABASES WAS CONDUCTED FOR RANDOMIZED CONTROLLED TRIALS OF EXERCISE, YOGA, AND TAI CHI FOR MAJOR DEPRESSIVE DISORDER. DATA EXTRACTION: STANDARDIZED MEAN DIFFERENCES WERE CALCULATED AND META-ANALYZED USING A RANDOM EFFECTS MULTILEVEL MODELING FRAMEWORK. HETEROGENEITY AND SUBGROUP ANALYSIS WAS CONDUCTED. RESULTS: TWENTY-FIVE STUDIES WERE INCLUDED FOR FINAL ANALYSIS (EXERCISE: 15, YOGA: 7, TAI CHI: 3). OVERALL, META-ANALYSIS SHOWED A MODERATE SIGNIFICANT CLINICAL EFFECT. HOWEVER, WHEN ONLY STUDIES (6 STUDIES) WITH THE LOWEST RISK OF BIAS WERE INCLUDED, THE OVERALL EFFECT SIZE WAS REDUCED TO LOW TO MODERATE EFFICACY. OVERALL QUALITY OF EVIDENCE WAS LOW. HETEROGENEITY AND PUBLICATION BIAS WERE HIGH. CONCLUSIONS: THE CURRENT META-ANALYSIS OF OUTPATIENT EXERCISE, YOGA, AND TAI CHI FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER SUGGESTS THAT ADJUNCTIVE EXERCISE AND YOGA MAY HAVE SMALL ADDITIVE CLINICAL EFFECTS IN COMPARISON TO CONTROL FOR REDUCING DEPRESSIVE SYMPTOMS. THE EVIDENCE FOR TAI CHI IS INSUFFICIENT TO DRAW CONCLUSIONS. THE CONCERNS WITH QUALITY OF STUDIES, HIGH HETEROGENEITY, AND EVIDENCE OF PUBLICATION BIAS PRECLUDE MAKING FIRM CONCLUSIONS. 2020 14 1927 44 ROLE OF YOGA IN CARDIAC DISEASE AND REHABILITATION. PURPOSE: CARDIOVASCULAR DISEASE CONTINUES TO BE THE LEADING CAUSE OF MORBIDITY AND MORTALITY AROUND THE WORLD. YOGA, A COMBINATION OF PHYSICAL POSTURES (ASANA), BREATHING EXERCISES (PRANAYAMA), AND MEDITATION (DHYANA), HAS GAINED INCREASING RECOGNITION AS A FORM OF MIND-BODY EXERCISE. IN THIS NARRATIVE REVIEW, WE INTENDED TO REVIEW THE EMERGING EVIDENCE ASSESSING THE PHYSIOLOGIC AND CLINICAL EFFECTS OF YOGA ON THE CARDIOVASCULAR SYSTEM AND THE POTENTIAL ROLE OF YOGA AS A COMPONENT OF COMPREHENSIVE CARDIAC REHABILITATION. METHODS: WE SEARCHED PUBMED, GOOGLE SCHOLAR, EMBASE, AND COCHRANE DATABASES FOR LITERATURE RELATED TO CARDIOVASCULAR EFFECTS OF YOGA FROM INCEPTION UP UNTIL 2017. RESULTS: YOGA HAS BEEN SHOWN TO HAVE FAVORABLE EFFECTS ON SYSTEMIC INFLAMMATION, STRESS, THE CARDIAC AUTONOMIC NERVOUS SYSTEM, AND TRADITIONAL AND EMERGING CARDIOVASCULAR RISK FACTORS. CONCLUSIONS: YOGA HAS SHOWN PROMISE AS A USEFUL LIFESTYLE INTERVENTION THAT CAN BE INCORPORATED INTO CARDIOVASCULAR DISEASE MANAGEMENT ALGORITHMS. ALTHOUGH MANY INVESTIGATORS HAVE REPORTED THE CLINICAL BENEFITS OF YOGA IN REDUCING CARDIOVASCULAR EVENTS, MORBIDITY, AND MORTALITY, EVIDENCE SUPPORTING THESE CONCLUSIONS IS SOMEWHAT LIMITED, THEREBY EMPHASIZING THE NEED FOR LARGE, WELL-DESIGNED RANDOMIZED TRIALS THAT MINIMIZE BIAS AND METHODOLOGICAL DRAWBACKS. 2019 15 2583 52 YOGA FOR HEART RATE VARIABILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS. THE OBJECTIVE OF THIS SYSTEMATIC REVIEW IS TO SUMMARIZE AND CRITICALLY ASSESS THE EFFECTS OF YOGA ON HEART RATE VARIABILITY (HRV). NINE DATABASES WERE SEARCHED FROM THEIR INCEPTIONS TO JUNE 2014. WE INCLUDED RANDOMIZED CLINICAL TRIALS (RCTS) COMPARING YOGA AGAINST ANY TYPE OF CONTROL INTERVENTION IN HEALTHY INDIVIDUALS OR PATIENTS WITH ANY MEDICAL CONDITION. RISK OF BIAS WAS ASSESSED USING THE COCHRANE CRITERIA. TWO REVIEWERS PERFORMED THE SELECTION OF STUDIES, DATA EXTRACTION, AND QUALITY ASSESSMENTS INDEPENDENT OF ONE ANOTHER. FOURTEEN TRIALS MET THE INCLUSION CRITERIA. ONLY TWO OF THEM WERE OF ACCEPTABLE METHODOLOGICAL QUALITY. TEN RCTS REPORTED FAVOURABLE EFFECTS OF YOGA ON VARIOUS DOMAINS OF HRV, WHEREAS NINE OF THEM FAILED TO DO SO. ONE RCT DID NOT REPORT BETWEEN-GROUP COMPARISONS. THE META-ANALYSIS (MA) OF TWO TRIALS DID NOT SHOW FAVOURABLE EFFECTS OF YOGA COMPARED TO USUAL CARE ON E:I RATIO (N = 61, SMDS = 0.63; 95% CIS [-0.72 TO 1.99], P = 0.36; HETEROGENEITY: R(2) = 0.79, CHI(2) = 5.48, DF = 1, (P = 0.02); I(2) = 82%). THE MA ALSO FAILED TO SHOW STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN THE GROUPS REGARDING THE 30:15 RATIO (N = 61, SMDS = 0.20; 95% CIS [-0.43 TO 0.84], P = 0.53; HETEROGENEITY: R(2) = 0.07, CHI(2) = 1.45, DF = 1, (P = 0.23); I(2) = 31%). THE DATA FROM THE REMAINING RCTS WERE TOO HETEROGENEOUS FOR POOLING. THESE RESULTS PROVIDE NO CONVINCING EVIDENCE FOR THE EFFECTIVENESS OF YOGA IN MODULATING HRV IN PATIENTS OR HEALTHY SUBJECTS. FUTURE INVESTIGATIONS IN THIS AREA SHOULD OVERCOME THE MULTIPLE METHODOLOGICAL WEAKNESSES OF THE PREVIOUS RESEARCH. 2015 16 2860 49 YOGA-BASED EXERCISE IMPROVES HEALTH-RELATED QUALITY OF LIFE AND MENTAL WELL-BEING IN OLDER PEOPLE: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS. OBJECTIVE: HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND MENTAL WELL-BEING ARE ASSOCIATED WITH HEALTHY AGEING. PHYSICAL ACTIVITY POSITIVELY IMPACTS BOTH HRQOL AND MENTAL WELL-BEING. YOGA IS A PHYSICAL ACTIVITY THAT CAN BE MODIFIED TO SUITS THE NEEDS OF OLDER PEOPLE AND IS GROWING IN POPULARITY. WE CONDUCTED A SYSTEMATIC REVIEW WITH META-ANALYSIS TO DETERMINE THE IMPACT OF YOGA-BASED EXERCISE ON HRQOL AND MENTAL WELL-BEING IN PEOPLE AGED 60+. METHODS: SEARCHES WERE CONDUCTED FOR RELEVANT TRIALS IN THE FOLLOWING ELECTRONIC DATABASES; MEDLINE, EMBASE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, CINAHL, ALLIED AND COMPLEMENTARY MEDICINE DATABASE, PSYCINFO AND THE PHYSIOTHERAPY EVIDENCE DATABASE (PEDRO) FROM INCEPTION TO JANUARY 2017. TRIALS THAT EVALUATED THE EFFECT OF PHYSICAL YOGA ON HRQOL AND/OR ON MENTAL WELL-BEING IN PEOPLE AGED 60+ YEARS WERE INCLUDED. DATA ON HRQOL AND MENTAL WELL-BEING WERE EXTRACTED. STANDARDISED MEAN DIFFERENCES AND 95% CONFIDENCE INTERVALS (CI) WERE CALCULATED USING RANDOM EFFECTS MODELS. METHODOLOGICAL QUALITY OF TRIALS WAS ASSESSED USING THE PEDRO SCALE. RESULTS: TWELVE TRIALS OF HIGH METHODOLOGICAL QUALITY (MEAN PEDRO SCORE 6.1), TOTALLING 752 PARTICIPANTS, WERE IDENTIFIED AND PROVIDED DATA FOR THE META-ANALYSIS. YOGA PRODUCED A MEDIUM EFFECT ON HRQOL (HEDGES' G = 0.51, 95% CI 0.25-0.76, 12 TRIALS) AND A SMALL EFFECT ON MENTAL WELL-BEING (HEDGES' G = 0.38, 95% CI 0.15-0.62, 12 TRIALS). CONCLUSION: YOGA INTERVENTIONS RESULTED IN SMALL TO MODERATE IMPROVEMENTS IN BOTH HRQOL AND MENTAL WELL-BEING IN PEOPLE AGED 60+ YEARS. FURTHER, RESEARCH IS NEEDED TO DETERMINE THE OPTIMAL DOSE OF YOGA TO MAXIMISE HEALTH IMPACT. PROSPERO REGISTRATION NUMBER: (CRD42016052458). 2018 17 2540 53 YOGA FOR ANXIETY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. YOGA HAS BECOME A POPULAR APPROACH TO IMPROVE EMOTIONAL HEALTH. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE EFFECTIVENESS AND SAFETY OF YOGA FOR ANXIETY. MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, PSYCINFO, AND INDMED WERE SEARCHED THROUGH OCTOBER 2016 FOR RANDOMIZED CONTROLLED TRIALS (RCTS) OF YOGA FOR INDIVIDUALS WITH ANXIETY DISORDERS OR ELEVATED LEVELS OF ANXIETY. THE PRIMARY OUTCOMES WERE ANXIETY AND REMISSION RATES, AND SECONDARY OUTCOMES WERE DEPRESSION, QUALITY OF LIFE, AND SAFETY. RISK OF BIAS WAS ASSESSED USING THE COCHRANE TOOL. EIGHT RCTS WITH 319 PARTICIPANTS (MEAN AGE: 30.0-38.5 YEARS) WERE INCLUDED. RISK OF SELECTION BIAS WAS UNCLEAR FOR MOST RCTS. META-ANALYSES REVEALED EVIDENCE FOR SMALL SHORT-TERM EFFECTS OF YOGA ON ANXIETY COMPARED TO NO TREATMENT (STANDARDIZED MEAN DIFFERENCE [SMD] = -0.43; 95% CONFIDENCE INTERVAL [CI] = -0.74, -0.11; P = .008), AND LARGE EFFECTS COMPARED TO ACTIVE COMPARATORS (SMD = -0.86; 95% CI = -1.56, -0.15; P = .02). SMALL EFFECTS ON DEPRESSION WERE FOUND COMPARED TO NO TREATMENT (SMD = -0.35; 95% CI = -0.66, -0.04; P = .03). EFFECTS WERE ROBUST AGAINST POTENTIAL METHODOLOGICAL BIAS. NO EFFECTS WERE FOUND FOR PATIENTS WITH ANXIETY DISORDERS DIAGNOSED BY DIAGNOSTIC AND STATISTICAL MANUAL CRITERIA, ONLY FOR PATIENTS DIAGNOSED BY OTHER METHODS, AND FOR INDIVIDUALS WITH ELEVATED LEVELS OF ANXIETY WITHOUT A FORMAL DIAGNOSIS. ONLY THREE RCTS REPORTED SAFETY-RELATED DATA BUT THESE INDICATED THAT YOGA WAS NOT ASSOCIATED WITH INCREASED INJURIES. IN CONCLUSION, YOGA MIGHT BE AN EFFECTIVE AND SAFE INTERVENTION FOR INDIVIDUALS WITH ELEVATED LEVELS OF ANXIETY. THERE WAS INCONCLUSIVE EVIDENCE FOR EFFECTS OF YOGA IN ANXIETY DISORDERS. MORE HIGH-QUALITY STUDIES ARE NEEDED AND ARE WARRANTED GIVEN THESE PRELIMINARY FINDINGS AND PLAUSIBLE MECHANISMS OF ACTION. 2018 18 2568 48 YOGA FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: MIND-BODY MEDICAL INTERVENTIONS ARE COMMONLY USED TO COPE WITH DEPRESSION AND YOGA IS ONE OF THE MOST COMMONLY USED MIND-BODY INTERVENTIONS. THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY ASSESS AND META-ANALYZE THE EFFECTIVENESS OF YOGA FOR DEPRESSION. METHODS: MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, PSYCINFO, AND INDMED WERE SEARCHED THROUGH JANUARY 2013. RANDOMIZED CONTROLLED TRIALS (RCTS) OF YOGA FOR PATIENTS WITH DEPRESSIVE DISORDERS AND INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION WERE INCLUDED. MAIN OUTCOMES WERE SEVERITY OF DEPRESSION AND REMISSION RATES, SECONDARY OUTCOMES WERE ANXIETY, QUALITY OF LIFE, AND SAFETY. RESULTS: TWELVE RCTS WITH 619 PARTICIPANTS WERE INCLUDED. THREE RCTS HAD LOW RISK OF BIAS. REGARDING SEVERITY OF DEPRESSION, THERE WAS MODERATE EVIDENCE FOR SHORT-TERM EFFECTS OF YOGA COMPARED TO USUAL CARE (STANDARDIZED MEAN DIFFERENCE (SMD) = -0.69; 95% CONFIDENCE INTERVAL (CI) -0.99, -0.39; P < .001), AND LIMITED EVIDENCE COMPARED TO RELAXATION (SMD = -0.62; 95%CI -1.03, -0.22; P = .003), AND AEROBIC EXERCISE (SMD = -0.59; 95% CI -0.99, -0.18; P = .004). LIMITED EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS OF YOGA ON ANXIETY COMPARED TO RELAXATION (SMD = -0.79; 95% CI -1.3, -0.26; P = .004). SUBGROUP ANALYSES REVEALED EVIDENCE FOR EFFECTS IN PATIENTS WITH DEPRESSIVE DISORDERS AND IN INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION. DUE TO THE PAUCITY AND HETEROGENEITY OF THE RCTS, NO META-ANALYSES ON LONG-TERM EFFECTS WERE POSSIBLE. NO RCT REPORTED SAFETY DATA. CONCLUSIONS: DESPITE METHODOLOGICAL DRAWBACKS OF THE INCLUDED STUDIES, YOGA COULD BE CONSIDERED AN ANCILLARY TREATMENT OPTION FOR PATIENTS WITH DEPRESSIVE DISORDERS AND INDIVIDUALS WITH ELEVATED LEVELS OF DEPRESSION. 2013 19 2518 70 YOGA COMPARED TO NON-EXERCISE OR PHYSICAL THERAPY EXERCISE ON PAIN, DISABILITY, AND QUALITY OF LIFE FOR PATIENTS WITH CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. BACKGROUND: CHRONIC LOW BACK PAIN (CLBP) IS A COMMON AND OFTEN DISABLING MUSCULOSKELETAL CONDITION. YOGA HAS BEEN PROVEN TO BE AN EFFECTIVE THERAPY FOR CHRONIC LOW BACK PAIN. HOWEVER, THERE ARE STILL CONTROVERSIES ABOUT THE EFFECTS OF YOGA AT DIFFERENT FOLLOW-UP PERIODS AND COMPARED WITH OTHER PHYSICAL THERAPY EXERCISES. OBJECTIVE: TO CRITICALLY COMPARE THE EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, QUALITY OF LIFE WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION), PHYSICAL THERAPY EXERCISE. METHODS: THIS STUDY WAS REGISTERED IN PROSPERO, AND THE REGISTRATION NUMBER WAS CRD42020159865. RANDOMIZED CONTROLLED TRIALS (RCTS) OF ONLINE DATABASES INCLUDED PUBMED, WEB OF SCIENCE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, EMBASE WHICH EVALUATED EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, AND QUALITY OF LIFE WERE SEARCHED FROM INCEPTION TIME TO NOVEMBER 1, 2019. STUDIES WERE ELIGIBLE IF THEY ASSESSED AT LEAST ONE IMPORTANT OUTCOME, NAMELY PAIN, BACK-SPECIFIC DISABILITY, QUALITY OF LIFE. THE COCHRANE RISK OF BIAS TOOL WAS USED TO ASSESS THE METHODOLOGICAL QUALITY OF INCLUDED RANDOMIZED CONTROLLED TRIALS. THE CONTINUOUS OUTCOMES WERE ANALYZED BY CALCULATING THE MEAN DIFFERENCE (MD) OR STANDARDIZED MEAN DIFFERENCE (SMD) WITH 95% CONFIDENCE INTERVALS (CI) ACCORDING TO WHETHER COMBINING OUTCOMES MEASURED ON DIFFERENT SCALES OR NOT. RESULTS: A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS WERE INCLUDED IN THIS META-ANALYSIS. YOGA COULD SIGNIFICANTLY REDUCE PAIN AT 4 TO 8 WEEKS (MD = -0.83, 95% CI = -1.19 TO -0.48, P<0.00001, I2 = 0%), 3 MONTHS (MD = -0.43, 95% CI = -0.64 TO -0.23, P<0.0001, I2 = 0%), 6 TO 7 MONTHS (MD = -0.56, 95% CI = -1.02 TO -0.11, P = 0.02, I2 = 50%), AND WAS NOT SIGNIFICANT IN 12 MONTHS (MD = -0.52, 95% CI = -1.64 TO 0.59, P = 0.36, I2 = 87%) COMPARED WITH NON-EXERCISE. YOGA WAS BETTER THAN NON-EXERCISE ON DISABILITY AT 4 TO 8 WEEKS (SMD = -0.30, 95% CI = -0.51 TO -0.10, P = 0.003, I2 = 0%), 3 MONTHS (SMD = -0.31, 95% CI = -0.45 TO -0.18, P<0.00001, I2 = 30%), 6 MONTHS (SMD = -0.38, 95% CI = -0.53 TO -0.23, P<0.00001, I2 = 0%), 12 MONTHS (SMD = -0.33, 95% CI = -0.54 TO -0.12, P = 0.002, I2 = 9%). THERE WAS NO SIGNIFICANT DIFFERENCE ON PAIN, DISABILITY COMPARED WITH PHYSICAL THERAPY EXERCISE GROUP. FURTHERMORE, IT SUGGESTED THAT THERE WAS A NON-SIGNIFICANT DIFFERENCE ON PHYSICAL AND MENTAL QUALITY OF LIFE BETWEEN YOGA AND ANY OTHER INTERVENTIONS. CONCLUSION: THIS META-ANALYSIS PROVIDED EVIDENCE FROM VERY LOW TO MODERATE INVESTIGATING THE EFFECTIVENESS OF YOGA FOR CHRONIC LOW BACK PAIN PATIENTS AT DIFFERENT TIME POINTS. YOGA MIGHT DECREASE PAIN FROM SHORT TERM TO INTERMEDIATE TERM AND IMPROVE FUNCTIONAL DISABILITY STATUS FROM SHORT TERM TO LONG TERM COMPARED WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION). YOGA HAD THE SAME EFFECT ON PAIN AND DISABILITY AS ANY OTHER EXERCISE OR PHYSICAL THERAPY. YOGA MIGHT NOT IMPROVE THE PHYSICAL AND MENTAL QUALITY OF LIFE BASED ON THE RESULT OF A MERGING. 2020 20 2496 62 YOGA AS PART OF A PACKAGE OF CARE VERSUS NON-STANDARD CARE FOR SCHIZOPHRENIA. BACKGROUND: YOGA IS AN ANCIENT BODY-MIND PRACTICE WHICH ORIGINATED IN INDIA AND IS POPULAR IN THE WESTERN WORLD AS A FORM OF RELAXATION AND EXERCISE. IT HAS BEEN OF INTEREST FOR PEOPLE WITH SCHIZOPHRENIA TO DETERMINE THE EFFICACY OF YOGA DELIVERED AS A PACKAGE OF CARE VERSUS NON-STANDARD CARE. OBJECTIVES: TO EXAMINE THE EFFECTS OF YOGA AS PART OF A PACKAGE OF CARE VERSUS NON-STANDARD CARE FOR SCHIZOPHRENIA. SEARCH METHODS: WE SEARCHED THE COCHRANE SCHIZOPHRENIA GROUP TRIALS REGISTER (LATEST 15 MAY 2018) WHICH IS BASED ON REGULAR SEARCHES OF MEDLINE, PUBMED, EMBASE, CINAHL, BIOSS, AMED, PSYCHINFO, AND REGISTRIES OF CLINICAL TRIALS. WE SEARCHED THE REFERENCES OF ALL INCLUDED STUDIES. THERE ARE NO LANGUAGE, DATE, DOCUMENT TYPE, OR PUBLICATION STATUS LIMITATIONS FOR INCLUSION OF RECORDS IN THE REGISTER. SELECTION CRITERIA: ALL RANDOMISED CONTROLLED TRIALS (RCTS) INCLUDING PEOPLE WITH SCHIZOPHRENIA COMPARING YOGA AS PART OF A PACKAGE OF CARE WITH NON-STANDARD CARE. DATA COLLECTION AND ANALYSIS: THERE WERE NO DATA TO ANALYSE AS NO STUDIES MET THE INCLUSION CRITERIA. MAIN RESULTS: THE SEARCHES IDENTIFIED 30 STUDIES THAT COULD BE RELEVANT TO THIS REVIEW. AFTER CAREFUL INSPECTION, 29 WERE EXCLUDED AND ONE IS AWAITING CLASSIFICATION. NO DATA WERE AVAILABLE FOR ANALYSES. AUTHORS' CONCLUSIONS: IN VIEW OF THE LACK OF EVIDENCE FROM RCTS, IT IS CURRENTLY NOT POSSIBLE FOR US TO COMMENT ON THE USE OF YOGA AS PART OF A PACKAGE OF CARE VERSUS NON-STANDARD CARE. 2019